» Articles » PMID: 27006943

Characterization and Functions of Protease-Activated Receptor 2 in Obesity, Diabetes, and Metabolic Syndrome: A Systematic Review

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2016 Mar 24
PMID 27006943
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Proteinase-activated receptor 2 (PAR2) is a cell surface receptor activated by serine proteinases or specific synthetic compounds. Interest in PAR2 as a pharmaceutical target for various diseases is increasing. Here we asked two questions relevant to endothelial dysfunction and diabetes: How is PAR2 function affected in blood vessels? What role does PAR2 have in promoting obesity, diabetes, and/or metabolic syndrome, specifically via the endothelium and adipose tissues? We conducted a systematic review of the published literature in PubMed and Scopus (July 2015; search terms: par2, par-2, f2lr1, adipose, obesity, diabetes, and metabolic syndrome). Seven studies focused on PAR2 and vascular function. The obesity, diabetes, or metabolic syndrome animal models differed amongst studies, but each reported that PAR2-mediated vasodilator actions were preserved in the face of endothelial dysfunction. The remaining studies focused on nonvascular functions and provided evidence supporting the concept that PAR2 activation promoted obesity. Key studies showed that PAR2 activation regulated cellular metabolism, and PAR2 antagonists inhibited adipose gain and metabolic dysfunction in rats. We conclude that PAR2 antagonists for treatment of obesity indeed show early promise as a therapeutic strategy; however, endothelial-specific PAR2 functions, which may offset mechanisms that produce vascular dysfunction in diabetes, warrant additional study.

Citing Articles

Protease-activated receptor 2 deficient mice develop less angiotensin II induced left ventricular hypertrophy but more cardiac fibrosis.

Meyer Zu Schwabedissen A, Vergarajauregui S, Bertog M, Amann K, Engel F, Daniel C PLoS One. 2024; 19(12):e0310095.

PMID: 39637045 PMC: 11620577. DOI: 10.1371/journal.pone.0310095.


PAR2-mediated cellular senescence promotes inflammation and fibrosis in aging and chronic kidney disease.

Ha S, Kim H, Kim K, Kim B, Kim J, Son M Aging Cell. 2024; 23(8):e14184.

PMID: 38687090 PMC: 11320361. DOI: 10.1111/acel.14184.


Metabolic underpinnings of cancer-related fatigue.

Zhang X, Perry R Am J Physiol Endocrinol Metab. 2024; 326(3):E290-E307.

PMID: 38294698 PMC: 11901342. DOI: 10.1152/ajpendo.00378.2023.


Changes in Protease-Activated Receptor and Trypsin-1 Expression Are Involved in the Therapeutic Effect of Mg Supplementation in Type 2 Diabetes-Induced Gastric Injury in Male Adult Rats.

Mehranfard N, Rezazadeh H, Soltani N, Dastgerdi A, Rad M, Ghasemi M Adv Pharmacol Pharm Sci. 2023; 2023:5703718.

PMID: 37228689 PMC: 10205415. DOI: 10.1155/2023/5703718.


Characterization of Endothelium-Dependent Relaxation in the Saphenous Artery and Its Caudal Branches in Young and Old Adult Sprague Dawley Rats.

Wang A, Fraser G, McGuire J Biomolecules. 2022; 12(7).

PMID: 35883445 PMC: 9312764. DOI: 10.3390/biom12070889.


References
1.
McGuire J, Van Vliet B, Gimenez J, King J, Halfyard S . Persistence of PAR-2 vasodilation despite endothelial dysfunction in BPH/2 hypertensive mice. Pflugers Arch. 2007; 454(4):535-43. DOI: 10.1007/s00424-007-0226-2. View

2.
Li Y, Mihara K, Saifeddine M, Krawetz A, Lau D, Li H . Perivascular adipose tissue-derived relaxing factors: release by peptide agonists via proteinase-activated receptor-2 (PAR2) and non-PAR2 mechanisms. Br J Pharmacol. 2011; 164(8):1990-2002. PMC: 3246662. DOI: 10.1111/j.1476-5381.2011.01501.x. View

3.
McLean P, Aston D, Sarkar D, Ahluwalia A . Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers. Circ Res. 2002; 90(4):465-72. DOI: 10.1161/hh0402.105372. View

4.
Lohman R, Cotterell A, Suen J, Liu L, Do A, Vesey D . Antagonism of protease-activated receptor 2 protects against experimental colitis. J Pharmacol Exp Ther. 2011; 340(2):256-65. DOI: 10.1124/jpet.111.187062. View

5.
Oikonomopoulou K, Hansen K, Saifeddine M, Vergnolle N, Tea I, Blaber M . Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol Chem. 2006; 387(6):817-24. DOI: 10.1515/BC.2006.104. View